Paul Crosland

Paul Crosland

Auto-generated profile, based on publicly available information

Paul Crosland

Youth Mental Health and Technology, Brain and Mind Centre, Faculty of Medicine and Health, Central Clinical School, University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2015 in BMJ
Verified
Journal Article
Closed access
PDF file
CHCheryl Hookway
Cheryl Hookway
SBSara Buckner
Sara Buckner
PCPaul Crosland
Paul Crosland
DLDamien Longson
Damien Longson

4 March 2015 in BMJ
Verified
Journal Article
Closed access
PDF file
KHKathryn Hopkins
Kathryn Hopkins
PCPaul Crosland
Paul Crosland
NENicole Elliott
Nicole Elliott
SBSusan Bewley
Susan Bewley
OBOn behalf of the Clinical Guidelines Update Committee B
On behalf of the Clinical Guidelines Update Committee B

4 March 2019 in Australian and New Zealand Journal of Public Health
Verified
Journal Article
Open access
PDF file
PCPaul Crosland
Paul Crosland
JAJaithri Ananthapavan
Jaithri Ananthapavan
JDJacqueline Davison
Jacqueline Davison
MLMichael Lambert
Michael Lambert
RCRob Carter
Rob Carter
Objective: A systematic review was conducted to determine the health burden of preventable disease in Australia. Methods: The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) statement guidelines were followed to identify, screen and describe the protocols used in the systematic review. Results: Eleven studies were included in the review. Data on the health burden associated with lifestyle‐related risk factors were extracted by disease with outcomes reported in attributable number and proportion of deaths, years of life lost, years lived with disability and disability‐adjusted life years (DALYs). Around one‐third of DALYs was attributed to all modifiable risk factors. The range of estimates of DALYs attributable to each prioritised risk factor was: combined dietary risk factors, 7.2% to 9.7%; tobacco, 7.9% to 9.0%; alcohol, 5.1% to 12.2%; high body mass, 5.5% to 8.3%; and physical inactivity, 1.2% to 5.5%. Conclusions: Although the methods used to estimate preventable health burden varied greatly between studies, all found that a substantial amount of death and disability was attributable to lifestyle‐related risk factors. Implications for public health: There is a large health burden in Australia caused by modifiable risk factors and further action is warranted to address this burden.


1 August 2018 in Atherosclerosis
Verified
Journal Article
Open access
PCPaul Crosland
Paul Crosland
RMRoss Maconachie
Ross Maconachie
SBSara Buckner
Sara Buckner
HMHugh McGuire
Hugh McGuire
SHSteve Eric Humphries
Steve Eric Humphries
Nadeem QureshiNadeem Qureshi
Nadeem Qureshi
The cost effectiveness of cascade testing for familial hypercholesterolaemia (FH) is well recognised. Less clear is the cost effectiveness of FH screening when it includes case identification strategies that incorporate routinely available data from primary and secondary care electronic health records. Nine strategies were compared, all using cascade testing in combination with different index case approaches (primary care identification, secondary care identification, and clinical assessment using the Simon Broome (SB) or Dutch Lipid Clinic Network (DLCN) criteria). A decision analytic model was informed by three systematic literature reviews and expert advice provided by a NICE Guideline Committee. The model found that the addition of primary care case identification by database search for patients with recorded total cholesterol >9.3 mmol/L was more cost effective than cascade testing alone. The incremental cost-effectiveness ratio (ICER) of clinical assessment using the DLCN criteria was £3254 per quality-adjusted life year (QALY) compared with case-finding with no genetic testing. The ICER of clinical assessment using the SB criteria was £13,365 per QALY (compared with primary care identification using the DLCN criteria), indicating that the SB criteria was preferred because it achieved additional health benefits at an acceptable cost. Secondary care identification, with either the SB or DLCN criteria, was not cost effective, alone (dominated and dominated respectively) or combined with primary care identification (£63, 514 per QALY, and £82,388 per QALY respectively). Searching primary care databases for people at high risk of FH followed by cascade testing is likely to be cost-effective.

22 February 2022 in International Journal of Audiology
Verified
Journal Article
Closed access
KGKaryn Galvin
Karyn Galvin
Catherine Mary SucherCatherine Mary Sucher
Catherine Mary Sucher
RBRebecca Jane Bennett
Rebecca Jane Bennett
AEAzadeh Ebrahimi-Madiseh
Azadeh Ebrahimi-Madiseh
PCPaul Crosland
Paul Crosland
RERobert H. Eikelboom
Robert H. Eikelboom
To examine willingness to consider and to pay for various one-to-one telehealth appointments and online group training/information sessions amongst hearing service clients interested in future tele...